Tolulope Sharon Rumide

Tolulope Sharon Rumide

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
TAToufik Abdul-Rahman
Toufik Abdul-Rahman
PRPoulami Roy
Poulami Roy
RHRanferi Eduardo Herrera-Calderón
Ranferi Eduardo Herrera-Calderón
FKFeriha Fatima Khidri
Feriha Fatima Khidri
QOQuadri Ajibola Omotesho
Quadri Ajibola Omotesho
AAAthanasios Alexiou
Athanasios Alexiou
Breast cancer (BC) continues to be a significant global challenge due to drug resistance and severe side effects. The increasing prevalence is alarming, requiring new therapeutic approaches to address these challenges. At this point, Extracellular vesicles (EVs), specifically small endosome-released nanometer-sized EVs (SEVs) or exosomes, have been explored by literature as potential theranostics. Therefore, this review aims to highlight the therapeutic potential of exosomes in BC, focusing on their advantages in drug delivery and their ability to mitigate metastasis. Following the review, we identified exosomes' potential in combination therapies, serving as miRNA carriers and contributing to improved anti-tumor effects. This is evident in clinical trials investigating exosomes in BC, which have shown their ability to boost chemotherapy efficacy by delivering drugs like paclitaxel (PTX) and doxorubicin (DOX). However, the translation of EVs into BC therapy is hindered by various challenges. These challenges include the heterogeneity of EVs, the selection of the appropriate parent cell, the loading procedures, and determining the optimal administration routes. Despite the promising therapeutic potential of EVs, these obstacles must be addressed to realize their benefits in BC treatment.

20 June 2026 in In Silico Pharmacology
Verified
Journal Article
Closed access
TRTolulope Sharon Rumide
Tolulope Sharon Rumide
AOAbidemi Esther Ojo
Abidemi Esther Ojo
RGRegina Oghenevwede Golagha
Regina Oghenevwede Golagha
AAAanuoluwapo Alake
Aanuoluwapo Alake
ZSZainab Ajoke Suleiman
Zainab Ajoke Suleiman
MAMuhammed Robiu Asinmi
Muhammed Robiu Asinmi

12 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
LTLevi Tuwleh
Levi Tuwleh
JHJaveria Hamraa
Javeria Hamraa
Hassan AliHassan Ali
Hassan Ali
AEAdebayo Taiwo Emmanuel
Adebayo Taiwo Emmanuel
JBJosiah Talee Bropleh
Josiah Talee Bropleh
TRTolulope Sharon Rumide
Tolulope Sharon Rumide
In 2023, approximately 108 million infants worldwide received three doses of the diphtheria-tetanus-pertussis (DTP) vaccine, yet significant disparities persist, particularly in low-resource settings like West Africa. Despite the DPT vaccine's proven efficacy against diphtheria, the region continues to experience high rates of outbreaks for diphtheria, tetanus, and typhoid in 2024. This review aims to highlight the recent diphtheria crisis and analyze the trends and challenges of DTP vaccine coverage in West Africa by shedding light on socio-economic conditions, healthcare facilities and genetic factors. The review seeks to provide insights into improving vaccination rates and public health outcomes in the region, emphasizing the critical role of the DPT vaccine in combating life-threatening diseases. Enhanced surveillance and effective response strategies and development of region specific theraputics by the analysis of genomic variability in Africans, specifically within the human leukocyte antigen (HLA) locus are essential to address the ongoing public health challenges posed by diphtheria and related infections in West Africa.